Compare GoPro Inc (GPRO) vs Neurocrine Biosciences Inc (NBIX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GoPro Inc vs Neurocrine Biosciences Inc — how do they compare? GoPro Inc trades at $0.63 (market cap $114.41M), while Neurocrine Biosciences Inc trades at $156 (market cap $16.46B). The key difference: Neurocrine Biosciences Inc is far larger — about 143.9× GoPro Inc's market cap, and Neurocrine Biosciences Inc is trading nearer its 52-week high, GoPro Inc nearer its low. Which is the better fit depends on your goals.
| GPRO | NBIX | |
|---|---|---|
Market Cap | $114.41M | $16.46B |
Sector | Technology | Health |
52-Week High | $2.88 | $185.50 |
52-Week Low | $0.62 | $123.10 |
Enterprise Value | $173.19M | $16.48B |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GoPro Inc
GoPro Inc is a United States-based company that is principally engaged in designing and providing cameras, mounts, drones and appliances. The company outsources a part of manufacturing to third parties in China. The company sells products across the world through its direct sales channel, which generates over half of total revenue, and indirectly through its distribution channel. The company has presence, including in the Americas, Europe, Middle East, Africa, and Asia-Pacific, with the Americas contributing over half of total revenue.
Read more on GPRO →About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →
